Cardiac Sarcoidosis: When and How to Treat Inflammation-Reference-Cited by-同舟云学术

Cardiac Sarcoidosis: When and How to Treat Inflammation

Published:2021-11-22 Issue: Volume:7 Page:
ISSN:2057-7559
Container-title:Cardiac Failure Review
language:en
Short-container-title:Card Fail Rev

Author:

Giblin Gerard T¹^ORCID,Murphy Laura²^ORCID,Stewart Garrick C¹^ORCID,Desai Akshay S¹^ORCID,Di Carli Marcelo F²^ORCID,Blankstein Ron²^ORCID,Givertz Michael M¹^ORCID,Tedrow Usha B³^ORCID,Sauer William H³^ORCID,Hunninghake Gary M⁴^ORCID,Dellaripa Paul F⁴^ORCID,Divakaran Sanjay¹^ORCID,Lakdawala Neal K¹^ORCID

Affiliation:

1. Center for Advanced Heart Disease, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

2. Cardiovascular Imaging Program and Departments of Medicine and Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

3. Cardiac Arrhythmia Service, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

4. Interstitial Lung Disease Program, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

Abstract

Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.

Funder

Harvard Catalyst

Publisher

Radcliffe Group Ltd

Subject

General Medicine

Reference71 articles.

1. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77. https://doi.org/10.1161/CIRCULATIONAHA.109.851352; PMID: 19884472.

2. Hu X, Carmona EM, Yi ES, et al. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016;33:275–80. PMID: 27758994.

3. Iwai K, Takemura T, Kitaichi M, et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn 1993;43:377–85. https://doi.org/10.1111/j.1440-1827.1993.tb01149.x; PMID: 8372683.

4. Yafasova A, Fosbol EL, Schou M, et al. Long-term adverse cardiac outcomes in patients with sarcoidosis. J Am Coll Cardiol 2020;76:767–77. https://doi.org/10.1016/j.jacc.2020.06.038; PMID: 32792073.

5. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153–65. https://doi.org/10.1056/NEJMra071714; PMID: 18032765.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Emerging Specialty of Cardio-Rheumatology;Current Atherosclerosis Reports;2024-06-24

2. Exploring the Role of Genetics in Sarcoidosis and Its Impact on the Development of Cardiac Sarcoidosis;Cardiogenetics;2024-06-03

3. Sarcoidose Cardíaca: O Camaleão da Cardiologia;ABC Imagem Cardiovascular;2024-03-27

4. Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges;Journal of Clinical Medicine;2024-03-15

5. Cardiac Sarcoidosis: The Chameleon of Cardiology;ABC Imagem Cardiovascular;2024